Claims

1. Pharmaceutical formulation containing tamoxifen and endoxifen in a fixed dose combination wherein said fixed dose combination is calculated to compensate genotype- and/or phenotype-specific variations of the quantity and / or activity of CYP2D6, wherein the pharmaceutical formulation comprises 15–25 mg of tamoxifen and 0.25–5.0 mg of endoxifen.

2. Formulation according to Claim 1 for CYP2D6 IM patients comprising 15–25 mg of tamoxifen and 0.25–2.00 mg of endoxifen.

3. Formulation according to Claim 1 for CYP2D6 PM patients comprising 15–25 mg of tamoxifen and 1.0–5.0 mg of endoxifen.